Speaker Profile

Dr. Mohamed Ali Bedaiwy MD, PhD, FACOG, FRCSC is Professor with tenure and Division Head of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, the University of British Columbia, Vancouver, Canada. Dr. Bedaiwy is certified by the American Board of Obstetrics and Gynecology in OBGYN and REI, a fellow of the American College of Obstetrics and Gynecology and a fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Bedaiwy completed: - Residency in Obstetrics and Gynecology at the University Hospital Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA - Fellowship in Reproductive Endocrinology and Infertility at the University Hospital Case Medical Center, CWRU, Cleveland, Ohio, USA - Fellowship in Minimally Invasive Surgery at the Cleveland Clinic Foundation, Cleveland, Ohio, USA - Fellowship in Reproductive Endocrinology and Infertility in the Division of Reproductive Sciences, University of Toronto, Toronto, Canada - PhD from the University of Maastricht, The Netherlands for his work on ovarian tissue cryopreservation and transplantation Dr. Bedaiwy authored over 200 publications, including 108 peer-reviewed publications. He was cited more than 4600 times, with h-index of 34 and i10-index of 69 according to google scholar. He is best known for his work in endometriosis, ovarian transplantation, in vitro fertilization (IVF) and minimally invasive surgery (MIS). His interests include IVF, MIS, robotic surgery, fertility preservation in cancer patients, and endometriosis. He is also the Associate Editor of the Human Reproduction Journal which is the official journal of the European Society of Human Reproduction and Embryology (ESHRE). Dr. Bedaiwy has had a career-long interest in high quality medical care, research and education.
I have a relationship with a for-profit and/or a not-for-profit organization to disclose: - Membership on advisory boards or speakers' bureaus: Consultant for Abbvie - Funded grants or clinical trials: Consultant for Allergan I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (i.e. “off-label” use of medication). I do not acknowledge that the National Standard requires that any description of therapeutic options utilize generic names (or both generic and trade names) and not reflect exclusivity and branding.